Overview

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
Phase:
Phase 2
Details
Lead Sponsor:
ImmuneMed, Inc.
Treatments:
Antibodies, Monoclonal